Moderately Proteinuric IgA Nephropathy in the Young, Vol. 44 Book

1	Pathogenetic Aspects of IgAN	1
2	Natural History and Clinical Factors of Progression	7
3	Treatment of IgAN	11
4	Rationale Bases for the Use of Angiotensin Converting Enzyme Inhibitors (ACE-I) in IgAN	14
5	Biomed Study Design	18
6	Study Design and Outcome Evaluation. Statistical Methods	29
7	Clinical Characteristic of the Young Patients Affected by IgAN Characterised by Detectable Non-nephrotic Proteinuria	31
8	Normotension and Hypertension in IgAN	44
9	Confocal Laser Scanning Microscopy	49
10	IgA Nephropathy and Polymorphism of HLA class II genes	55
11	Polymorphisms in the MBL2 Promoter are not Correlated with IgA Nephropathy	67
12	Angiotensin Converting Enzyme and Angiotensin II type 1 Receptor Gene Polymorphism	75
13	Polymorphism of Adducin Gene	78
14	Preliminary Analysis of Uteroglobin Gene Polymorphism in IgA Nephropathy	83
15	Macromolecular IgA and IgA with Altered Glycosylation	88
16	Blastokinin/Uteroglobin in Sera of IgAN Patients	97
17	C4, BF, C3 Allele Distribution in IgA Nephropathy	104
18	IL-6, IL-8, MCP-1 and EGF Urinary Cytochine Excretion in IgA Nephropathy	113
19	Overview on Biomed 2 IgACE Study Achievements and Future Program	119
	App. 1: Project management structure	124
	App. 2: List of partners and non-partner contributors	125
	Author Index	133